FreedomWorks Foundation Statement in Response to the Trump Administration’s Executive Order on Prescription Drug Pricing

WASHINGTON, D.C. — In response to an executive order issued by President Trump ordering price controls to be placed on prescription drugs in America, Adam Brandon, FreedomWorks President commented:

“We are immensely disappointed that the administration has decided to tout price controls as an answer to America’s rising prescription drug prices. Tying prices in the United States to those of nations which have implemented socialist price restrictions will only ensure that America inherits the wait times and shortages seen in those countries.

“In particular, the most favored nation provision would ensure that America becomes one of the least attractive places on earth to invest in pharmaceutical research and development. This will have profound consequences that will reverberate through the entire economy.

“We are encouraged that the administration has decided to delay implementation of this order for one month. We hope they will come to a better conclusion in that timeframe. We look forward to our activists making their voices heard on this issue and hope the administration will ultimately reconsider.”

Related Content